

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19904

Title: Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

Reviewer's code: 02439915

Reviewer's country: China

Science editor: Jing Yu

Date sent for review: 2015-05-27 08:23

Date reviewed: 2015-07-28 16:50

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a more comprehensive and interesting literature review. The content is novel and the evidence is sufficient. 1. The third part of the review on GPC3 immunohistochemistry is no new content, it is recommended to reduce the number of words.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19904

Title: Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

Reviewer's code: 02936084

Reviewer's country: Egypt

Science editor: Jing Yu

Date sent for review: 2015-05-27 08:23

Date reviewed: 2015-07-29 03:11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear colleagues Hallo, I hope you are fine. Manuscript titled " Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma by Haruyama et al. - The authors discussed the prognostic role and the therapeutic target Of Glypican-3 in hepatocellular carcinoma. In spite that this idea was previously discussed even in very recent met analysis studies, the authors write very organized review article. The titles of different parts of the review are very confirmative. The language is excellent. The part of GPC3-targeting immunotherapy is very organized and informative . But I think that the illustrations are not enough eg. there is no figure to demonstrate the complex between GPC3 with Wnt/ β -catenin. Also role of glypican in the progression of HCC must be supplemented with some figures. I recommend to accept this review article after adding these figures.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19904

Title: Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

Reviewer's code: 00036318

Reviewer's country: Greece

Science editor: Jing Yu

Date sent for review: 2015-05-27 08:23

Date reviewed: 2015-06-29 16:00

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[Y] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[Y] Accept
[] Grade B: Very good	[] Grade B: Minor language polishing	[] The same title	[] High priority for publication
[] Grade C: Good	[] Grade C: A great deal of language polishing	[] Duplicate publication	[] Rejection
[] Grade D: Fair	[] Grade D: Rejected	[Y] No	[] Minor revision
[] Grade E: Poor		BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is a comprehensive review of the potential role of glypican-3 as a diagnostic marker, a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. The review is well-structured, updated and covers all aspects of the topic.